Homburger: VectivBio loan agreement of upto USD75 m with Kreos Capital
VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, has entered into a loan agreement with Kreos Capital, a global growth lender to life sciences and healthcare companies, granting VectivBio access to a up to USD 75 m flexible loan facility.
Homburger advised VectivBio with regard to all Swiss legal and tax aspects of the financing transaction. The Homburger team included partner Andreas Müller (corporate / m&a, life sciences, pictured), lead associate Stefan Bindschedler (financing and investment products), partners Jürg Frick (financing and investment products), Stefan Oesterhelt (tax) and Luca Dal Molin (IP / IT) as well as associates Kevin Hubacher, Angela Oppliger (both corporate / m&a) and Kevin Müller (tax).
